Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 1825-1835

  Rouhollah, Khodadust ^a   Pelin, Mutlu ^a   Serap, Yalcin ^b   Gozde, Unsoy ^a   Ufuk, Gunduz ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b AHI EVRAN UNIVERSITY   (Turkey)

Author keywords

Cancer; Controlled release; Doxorubicin; Drug delivery system; PAMAM dendrimer coated magnetic nanoparticles; Stability; Targeted drug delivery

Indexed keywords

DENDRIMER; DOXORUBICIN; DRUG CARRIER; MAGNETIC NANOPARTICLE; POLYAMIDOAMINE; SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; HUMAN; HUMAN TISSUE; IC 50; MAGNETIC FIELD; MAGNETIC SEPARATION; NANOTECHNOLOGY; PH; SERUM; TEMPERATURE SENSITIVITY;

EID: 84877924726     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23524     Document Type: Article

References (62)

1. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25:2097-2116.
2. Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med 53:615-27.
3. Jang SH, Wientjes MG, Lu D, Au JL. 2003. Drug delivery and transport to solid tumors. Pharm Res 20:1337-1350.
4. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-6392.
5. Nune SK, Gunda P, Thallapally PK, Lin YY, Forrest ML, Berkland CJ. 2009. Nanoparticles for biomedical imaging. Expert Opin Drug Deliv 6:1175-1194.
6. Sun C, Lee JSH, Zhang MQ. 2008. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60:1252-1265.
7. Gupta AK, Gupta M. 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995-4021.
8. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. 2007. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2:23-39.
9. Yiyun C, Na M, Tongwen X, Rongqiang F, Xueyuan W, Xiaomin W, Longping W. 2007. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci-US 96:595-602.
10. Tomalia DA. 2004. Birth of a new macromolecular architecture: Dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichim Acta 37:39-57.
11. Tomalia DA, Esfand R. 1997. Dendrons, dendrimers and dendrigrafts. Chem Ind 11:416-420.
12. Bosman AW, Janssen HM, Meijer EW. 1999. About dendrimers: Structure, physical properties and applications. Chem Rev 99:1665-1688.
13. Lee I, Athey BD, Wetzel AW, Meixner W, Baker JR. 2002. Structural molecular dynamics studies on polyamidoamine dendrimers for a therapeutic application: Effects of pH and generation. Macromolecules 35:4510-4520.
14. Chen W, Tomalia DA, Thomas JL. 2000. Unusual pH-dependent polarity changes in PAMAM dendrimers: Evidence for pH-responsive conformational changes. Macromolecules 33:9169-9172.
15. Recker J, Tomcik DJ, Parquette JR. 2000. Folding dendrons: The development of solvent-, temperature-, and generation-dependent chiral conformational order in intramolecularly hydrogen-bonded dendrons. J Am Chem Soc 122:10298-10307.
16. Boas U, Karlsson AJ, de Waal BFM, Meijer EW. 2001. Synthesis and properties of new thiourea-functionalized poly(propylene imine) dendrimers and their role as hosts for urea functionalized guests. J Org Chem 66:2136-2145.
17. Patri AK, Majoros IJ, Baker JR. 2002. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 6:466-471.
18. Svenson S, Tomalia DA. 2005. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 57:2106-2129.
19. Yang W, Cheng Y, Xu T, Wang X, Wen LP. 2009. Targeting cancer cells with biotin e dendrimer conjugates. Eur J Med Chem 44:862-868.
20. Jansen JFGA, Debrabandervandenberg EMM, Meijer EW. 1994. Encapsulation of guest molecules into a dentritic box. Science 266:1226-1229.
21. Majoros IJ, Myc A, Thomas TP, Mehta CB, Baker JR. 2006. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 7:572-579.
22. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR. 2005. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 48:3729-3735.
23. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR. 2005. Tumor angiogenic vasculature targeting with PAMAM dendrimer RGD conjugates. Chem Commun 46:5739-5741.
24. Bhadra D, Yadav AK, Bhadra S, Jain NK. 2005. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 295:221-233.
25. Majoros IJ, Thomas TP, Mehta CB, Baker JR. 2005. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 48:5892-5899.
26. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. 2009. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30:3476-3485.
27. Schnyder A, Krahenbuhl S, Torok M, Drewe J, Huwyler J. 2004. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377:61-67.
28. Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S. 2011. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT. Anticancer Res 31:897-906.
29. Singh P, Gupta U, Asthana A, Jain NK. 2008. Folate and folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19:2239-2252
30. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Konishi J, Togashi K, Brechbiel MW. 2001. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn Reson Med 46:781-788.
31. Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother 44:2471-2474.
32. Roberts JC, Bhalgat MK, Zera RT. 1996. Preliminary biological evaluation of poly(amidoamine) (PAMAM) starburst dendrimers. J Biomed Mater Res 30:53-65.
33. Abaan OD, Mutlu PK, Baran Y, Atalay C, Gunduz U. 2009. Multi-drug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest 27(2):201-205.
34. Zou A, Chen Y, Huo M, Wang J, Zhang Y, Zhou J, Zhang Q. 2013. In vivo studies of octreotide-modified N-Octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery. J Pharm Sci 102(1):126-135.
35. Ye WL, Teng ZH, Liu DZ, Cui H, Liu M, Cheng Y, Yang TH, Mei QB, Zhou SY. 2013. Synthesis of a New pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro. J Pharm Sci 102(2):530-540.
36. Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J. 2006. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26:4559-4568.
37. Unsoy G, Yalcin S, Khodadust R, Gunduz G, Gunduz U. 2012. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. J Nanopart Res 14:964-977.
38. Khodadust, R, Ünsoy, G, Yalçin, S, Gündüz, G, Gündüz, U. 2013 PAMAM dendrimer coated iron oxide nanoparticles: Synthesis and characterization of different generations. J Nanopart Res 15:1488.
39. Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, Li Q, Xu P, Huang T. 2007. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 67:8156-8163.
40. Gao F, Pan BF, Zheng WM, Ao LM, Gu HC. 2005. Study of streptavidin coated onto PAMAM dendrimer modified magnetite nanoparticles. J Magn Magn Mater 293:48-54.
41. Esfand R, Tomalia DA. 2001. Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discov Today 6:427-436.
42. Lai PS, Lou PJ, Peng CL, Pai CL, Yen WN, Huang MY, Young TH, Shieh MJ. 2007. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release 122:39-46.
43. Rahman O, Mohapatra SC, Ahmad S. 2012. Fe3O4 inversespinal super paramagnetic nanoparticles. Mater Chem Phys 132: 196-202.
44. Brothers II HM, Piehler LT, Tomalia DA. 1998. Slab-gel and capillary electrophoretic characterization of polyamidoamine dendrimers. J Chromatogr 814:233-246.
45. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. 1986. Dendritic macromolecules: Synthesis of starburst dendrimers. Macromolecules 19:2466-2468.
46. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. 2005. Doxorubicin PAMAM dendrimer complex attached to liposomes: Cytotoxic studies against human cancer cell lines. Int J Pharm 302:29-38.
47. Mattiasson G. 2004. Flow cytometric analysis of isolated liver mitochondria to detect changes relevant to cell death. Cytometry A 60:145-154.
48. Labieniec M, Watala C. 2009. PAMAM dendrimers-Diverse biomedical applications. Facts and unresolved questions. Cent Eur J Biol 4:434-451.
49. Acharya S, Dilnawaz F, Sahoo SK. 2009. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30:5737-5750.
50. Schmid R. 2001. Recent advances in the description of the structure of water, the hydrophobic effect, and the like-dissolves-like rule. Monatshefte für Chemie 132:1295-1326.
51. Tsai HC, Imae T. 2011. Fabrication of dendrimers toward biological applications. In Nanoparticles in translational science and medicine; Villaverde A, Ed. Vol. VI. California: Academic Press, pp 101-132.
52. Jansen JF, de Brabander-van den Berg EM, Meijer EW. 1994. Encapsulation of guest macromolecules into a dendritic box. Science 266:1226-1229.
53. Min KH, Park K, Kim YS, Bae SM, Lee S, Jo HG, Park RW, Kim IS, Jeong SY, Kim K, Kwon IC. 2008. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 127:208-218.
54. Ducry L, Stump B. 2010. Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chem 21:5-13.
55. Clarke SJ, Rivory LP. 1999. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36 (2):99-114.
56. Johnson IS, Armstrong JG, Gorman M, Burnett JP. 1963. The vinca alkaloids: A new class of oncolytic agents. Cancer Res 23:1390-1427.
57. Lee I, Athey BD, Wetzel AW, Meixner W, Baker JR. 2002. Structural molecular dynamics studies on polyamidoamine dendrimers for a therapeutic application: Effects of pH and generation. Macromolecules 35:4510-4520.
58. Chen W, Tomalia DA, Thomas JL. 2000. Unusual pH-dependent polarity changes in PAMAM dendrimers: Evidence for pH-responsive conformational changes. Macromolecules 33:9169-9172.
59. Zyad A, Bénard J, Tursz T, Clarke R, Chouaib S. 1994. TNF gene expression cancer MCF-7 cell line: Relationship to MDR1, MnSOD, and resistance to TNF-a and adriamycin in the human breast. Cancer Res 54:825-831.
60. Schmaljohann D. 2006. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliver Rev 58:1655-1670.
61. de Las Heras Alarcon C, Pennadom, S, Alexander C. 2005. Stimuli-responsive polymers for biomedical applications. Chem Soc Rev 34:276-285.
62. Gillies ER, Fréchet JM. 2005. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 16:361-368.